
ACOGF
Healthcare · Biotechnology · $35.7M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2024
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 13, 2024 | Time not confirmed | -0.04 | -0.01 | +75.0% |
| May 14, 2024 | After the close | — | -0.05 | — |
| Nov 28, 2023 | After the close | — | -0.03 | — |
| Aug 22, 2023 | After the close | — | -0.03 | — |
| May 30, 2023 | After the close | — | -0.02 | — |
| Mar 8, 2023 | After the close | -0.03 | -0.05 | -66.7% |
| Nov 28, 2022 | After the close | -0.05 | -0.04 | +20.0% |
| Aug 25, 2022 | After the close | -0.05 | -0.04 | +20.0% |
| May 30, 2022 | After the close | -0.06 | -0.07 | -16.7% |
| Nov 26, 2021 | After the close | — | -0.09 | — |
Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative…